Abstract 570: PD-L1 expression in paired non-small cell lung cancer tumor samples
Henrik Hager(Aarhus University Hospital), Jeanette Bæhr Georgsen(Aarhus University Hospital), Jong‐Mu Sun(Samsung Medical Center), Peter Meldgaard(Aarhus University Hospital), Kenneth Emancipator(Merck & Co., Inc., Rahway, NJ, USA (United States)), Marisa Dolled‐Filhart(Fox Chase Cancer Center), Dianna Wu(Memorial Sloan Kettering Cancer Center), Zhen Wang(Ministry of Education), Steffen Filskov Sorensen(Aarhus University Hospital), Yoon‐La Choi(Samsung Medical Center), Wei Zhou(Broad Institute)
Cited by 0
Related Papers
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
|Journal of Clinical Oncology|2016|859
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
|Clinical Cancer Research|2015|799
Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma
|Journal of Clinical Oncology|2016|679